v3.26.1
Share based compensation reserve - Director and Senior Management Share Awards (Details)
€ in Millions
6 Months Ended
Jun. 22, 2026
shares
Jun. 22, 2026
Jul. 10, 2025
shares
Jul. 10, 2024
Jun. 30, 2026
EUR (€)
shares
Jun. 30, 2025
EUR (€)
shares
Key Management Personnel Of Entity Or Parent, Non-Executive Director [Member]            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
New awards granted in the period (in shares)   94,110 49,092 36,738    
Awards vested and issued in period (in shares) (49,092) (29,707)       (24,135)
Liabilities from share-based payment transactions (in shares) 19,385   12,603      
New awards granted in the period (in shares)   94,110 49,092 36,738    
Share based compensation reserve | Key Management Personnel Of Entity Or Parent, Non-Executive Director [Member]            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Share based payment charge | €         € 0.4 € 0.3
Share based compensation reserve | Key management personnel of entity or parent            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Share based payment charge | €         (3.3) 3.8
Share based compensation reserve | Key Management Personnel Of Entity Or Parent, Reclassification to tax liability            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Reclassification of awards for settlement of tax liabilities | €         € (0.8) € (12.2)
Restricted shares            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Number of other equity instruments outstanding (in shares) at beginning of period         3,285,141 3,128,416
New awards granted in the period (in shares)         1,213,028 1,159,853
Forfeitures in the period (in shares)         (1,163,301) (324,575)
Awards vested and issued in period (in shares)         (49,000) (631,994)
Number of other equity instruments outstanding (in shares) at end of period         3,285,868 3,331,700
New awards granted in the period (in shares)         1,213,028 1,159,853
Restricted shares | January 1, 2022            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Awards vested and issued in period (in shares)           (349,823)
Liabilities from share-based payment transactions (in shares)           282,171
Restricted shares | Other Awards            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Awards vested and issued in period (in shares)         (56,000) (62,000)
Restricted shares | January 1, 2022            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Number of other equity instruments outstanding (in shares) at beginning of period           704,983
New awards granted in the period (in shares)           0
Forfeitures in the period (in shares)           (148,989)
Awards vested and issued in period (in shares)           (555,994)
Number of other equity instruments outstanding (in shares) at end of period           0
New awards granted in the period (in shares)           0
Restricted shares | Other Awards            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Number of other equity instruments outstanding (in shares) at beginning of period         589,991 441,991
New awards granted in the period (in shares)         56,000 62,000
Forfeitures in the period (in shares)         (21,167) (20,000)
Awards vested and issued in period (in shares)         (49,000) (76,000)
Number of other equity instruments outstanding (in shares) at end of period         575,824 407,991
New awards granted in the period (in shares)         56,000 62,000
Restricted shares | January 1, 2023            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Number of other equity instruments outstanding (in shares) at beginning of period         777,155 922,250
New awards granted in the period (in shares)         0 0
Forfeitures in the period (in shares)         (777,155) (69,759)
Awards vested and issued in period (in shares)         0  
Number of other equity instruments outstanding (in shares) at end of period         0 852,491
New awards granted in the period (in shares)         0 0
Restricted shares | January 1, 2024            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Number of other equity instruments outstanding (in shares) at beginning of period         873,507 1,059,192
New awards granted in the period (in shares)         0 0
Forfeitures in the period (in shares)         (79,852) (71,935)
Awards vested and issued in period (in shares)         0  
Number of other equity instruments outstanding (in shares) at end of period         793,655 987,257
New awards granted in the period (in shares)         0 0
Performance and Restricted Stock | January 1, 2025            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Number of other equity instruments outstanding (in shares) at beginning of period         1,044,488 0
New awards granted in the period (in shares)         0 1,097,853
Forfeitures in the period (in shares)         (210,240) (13,892)
Awards vested and issued in period (in shares)         0  
Number of other equity instruments outstanding (in shares) at end of period         834,248 1,083,961
New awards granted in the period (in shares)         0 1,097,853
Performance and Restricted Stock | January 1, 2026            
Disclosure of terms and conditions of share-based payment arrangement [line items]            
Number of other equity instruments outstanding (in shares) at beginning of period         0  
New awards granted in the period (in shares)         1,157,028  
Forfeitures in the period (in shares)         (74,887)  
Awards vested and issued in period (in shares)         0  
Number of other equity instruments outstanding (in shares) at end of period         1,082,141  
New awards granted in the period (in shares)         1,157,028